Latest Insider Transactions at Biohaven Pharmaceutical Holding CO Ltd. (BHVN)
This section provides a real-time view of insider transactions for Biohaven Pharmaceutical Holding CO Ltd. (BHVN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Biohaven Pharmaceutical Holding Co Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Biohaven Pharmaceutical Holding Co Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
10,000
-100.0%
|
$1,480,000
$148.5 P/Share
|
|
Oct 03
2022
|
John W Childs |
SELL
Sale (or disposition) back to the issuer
|
Direct |
3,025,001
-100.0%
|
$447,700,148
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
830,891
-47.14%
|
$122,971,868
$148.5 P/Share
|
|
Oct 03
2022
|
Vlad Coric Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
92,050
-9.97%
|
$13,623,400
$148.5 P/Share
|
|
Oct 03
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Sale (or disposition) back to the issuer
|
Direct |
14,226
-100.0%
|
$2,105,448
$148.5 P/Share
|
|
Oct 03
2022
|
Robert J Hugin |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,900
-100.0%
|
$429,200
$148.5 P/Share
|
|
Oct 03
2022
|
Matthew Buten Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
6,177
-100.0%
|
$914,196
$148.5 P/Share
|
|
Oct 03
2022
|
Kishan Mehta |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,640
-100.0%
|
$1,574,720
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
1,614
-100.0%
|
$238,872
$148.5 P/Share
|
|
Oct 03
2022
|
John Tilton Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
5,068
-75.85%
|
$750,064
$148.5 P/Share
|
|
Oct 03
2022
|
James Engelhart Strategic Advisor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,900
-100.0%
|
$2,353,200
$148.5 P/Share
|
|
Oct 03
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
4,292
-100.0%
|
$635,216
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,374
-100.0%
|
$795,352
$148.5 P/Share
|
|
Oct 03
2022
|
Elyse Stock Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,090
-100.0%
|
$1,641,320
$148.5 P/Share
|
|
Oct 03
2022
|
Charles Conway Chief Scientific Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
22,362
-100.0%
|
$3,309,576
$148.5 P/Share
|
|
Oct 03
2022
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Sale (or disposition) back to the issuer
|
Direct |
11,653
-100.0%
|
$1,724,644
$148.5 P/Share
|
|
Oct 03
2022
|
Gregory Bailey |
SELL
Sale (or disposition) back to the issuer
|
Direct |
2,583,658
-100.0%
|
$382,381,384
$148.5 P/Share
|
|
Aug 19
2022
|
Gregory Bailey |
BUY
Open market or private purchase
|
Direct |
38,000
+1.45%
|
$5,624,000
$148.04 P/Share
|
|
May 10
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,200
-50.82%
|
$592,200
$141.5 P/Share
|
|
May 10
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,250
+21.4%
|
$119,250
$53.76 P/Share
|
|
Jan 19
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
9,375
-20.09%
|
$1,096,875
$117.09 P/Share
|
|
Jan 19
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,670
+16.43%
|
$243,810
$43.09 P/Share
|
|
Jan 10
2022
|
Kishan Mehta |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+14.98%
|
-
|
|
Jan 10
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
937
+14.85%
|
-
|
|
Jan 10
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
464
-4.56%
|
$59,392
$128.87 P/Share
|
|
Jan 10
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+8.94%
|
-
|
|
Jan 07
2022
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,634
-10.98%
|
$593,152
$128.87 P/Share
|
|
Jan 07
2022
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+19.15%
|
-
|
|
Jan 07
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
1,631
-10.44%
|
$208,768
$128.87 P/Share
|
|
Jan 07
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+19.35%
|
-
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,000
+18.39%
|
-
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,539
-12.19%
|
$196,992
$128.87 P/Share
|
|
Jan 07
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+20.47%
|
-
|
|
Jan 07
2022
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,279
-7.54%
|
$163,712
$128.87 P/Share
|
|
Jan 07
2022
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,250
+16.09%
|
-
|
|
Jan 07
2022
|
George C. Clark VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
522
-5.38%
|
$66,816
$128.87 P/Share
|
|
Jan 07
2022
|
George C. Clark VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+9.34%
|
-
|
|
Jan 07
2022
|
John Tilton Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
342
-6.48%
|
$43,776
$128.87 P/Share
|
|
Jan 07
2022
|
John Tilton Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
875
+14.22%
|
-
|
|
Jan 06
2022
|
Vlad Coric Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,854
-15.38%
|
$720,042
$123.86 P/Share
|
|
Jan 06
2022
|
Vlad Coric Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+24.72%
|
-
|
|
Jan 06
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
SELL
Payment of exercise price or tax liability
|
Direct |
2,230
-15.8%
|
$274,290
$123.86 P/Share
|
|
Jan 06
2022
|
William A Jones Jr CCO-Migraine & Common Disease |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+26.16%
|
-
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,250
+26.67%
|
-
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,838
-16.39%
|
$226,074
$123.86 P/Share
|
|
Jan 06
2022
|
Elyse Stock Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+25.06%
|
-
|
|
Jan 06
2022
|
James Engelhart Strategic Advisor |
SELL
Payment of exercise price or tax liability
|
Direct |
1,532
-10.06%
|
$188,436
$123.86 P/Share
|
|
Jan 06
2022
|
James Engelhart Strategic Advisor |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+19.75%
|
-
|
|
Jan 06
2022
|
Kimberly Gentile SVP, Clinical Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,800
-13.38%
|
$221,400
$123.86 P/Share
|
|
Jan 06
2022
|
Kimberly Gentile SVP, Clinical Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
3,750
+21.8%
|
-
|